Biome Australia Ltd
ASX:BIO
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.12
0.825
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Biome Australia Ltd
Cost of Revenue
Biome Australia Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Biome Australia Ltd
ASX:BIO
|
Cost of Revenue
-AU$5.1m
|
CAGR 3-Years
-65%
|
CAGR 5-Years
-97%
|
CAGR 10-Years
N/A
|
|
|
Bioxyne Ltd
ASX:BXN
|
Cost of Revenue
-AU$5.9m
|
CAGR 3-Years
-79%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
-17%
|
|
|
McPherson's Ltd
ASX:MCP
|
Cost of Revenue
-AU$68.1m
|
CAGR 3-Years
16%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
|
Star Combo Pharma Ltd
ASX:S66
|
Cost of Revenue
-AU$20.3m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Elixinol Wellness Ltd
ASX:EXL
|
Cost of Revenue
-AU$4.8m
|
CAGR 3-Years
17%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hydration Pharmaceuticals Co Ltd
ASX:HPC
|
Cost of Revenue
-$4.6m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
Biome Australia Ltd
Glance View
Biome Australia Ltd. engages in the development and marketing of live biotherapeutics and complementary medicines. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-11-30. The firm licenses, develops and markets evidence-based, complementary medicines, including nutraceuticals (food-based vitamins and weight management products) and live biotherapeutics (probiotics). The company markets and distributes clinically researched products developed in conjunction with its strategic partners. Its products include 22 products marketed under three brands, being Activated Probiotics, Activated Nutrients and Activated X Performance. These products are distributed through community pharmacies, independent health practitioners and online direct to consumer channels. The company offers biotherapeutic products to help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and irritable bowel syndrome (IBS), through randomized double-blind placebo-controlled trials.
See Also
What is Biome Australia Ltd's Cost of Revenue?
Cost of Revenue
-5.1m
AUD
Based on the financial report for Jun 30, 2024, Biome Australia Ltd's Cost of Revenue amounts to -5.1m AUD.
What is Biome Australia Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-97%
Over the last year, the Cost of Revenue growth was -72%. The average annual Cost of Revenue growth rates for Biome Australia Ltd have been -65% over the past three years , -97% over the past five years .
You don't have any saved screeners yet
